Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 11, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific insider transaction and does not contain financial statements or performance metrics.
Material Changes
The only material change reported is a transaction involving Mrs. L Greig on May 8, 2006, consisting of the sale of 600 ADSs at a price of $57.15 per ADS. The company was advised of this transaction on May 11, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It strictly adheres to the requirements of Disclosure Rule 3.1.4R(1)(a) regarding the notification of the aforementioned transaction.
Investor Verification Points
- Verify the identity of the connected person, Mrs. L Greig, and her role within the company.
- Confirm the transaction date (May 8, 2006) and the execution price ($57.15 per ADS).
- Review the total number of ADSs sold (600) to assess the significance relative to the individual's total holdings.